Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2334303 | 1.00 | SRD5A2 (0.38) | SRD5A2CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL2319038 | 0.93 | SRD5A2 (0.39) | SRD5A2CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL2339044 | 0.93 | SRD5A2 (0.39) | SRD5A2CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL12973080 | 0.88 | SRD5A2 (0.39) | SRD5A2CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL2342637 | 0.83 | SRD5A2 (0.36) | SRD5A2 | |
| SCHEMBL10532677 | 0.83 | SRD5A2 (0.37) | SRD5A2 | |
| SCHEMBL10536204 | 0.81 | SRD5A2 (0.37) | SRD5A2 | |
| SCHEMBL3645281 | 0.79 | SRD5A2 (0.45) | SRD5A2CYP3A4CYP2C9CYP2C19TDP1 | |
| SCHEMBL6841929 | 0.78 | SRD5A2 (0.47) | SRD5A2CYP19A1 | |
| SCHEMBL6841928 | 0.78 | SRD5A2 (0.47) | SRD5A2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0201452-B1 | PROCESS FOR THE PREPARATION OF 17-ALPHA-ETHYNYL-17-BETA-HYDROXY-18-METHYL-ESTRA-4,15-DIEN-3-ONE AND THE STARTING PRODUCTS FOR THIS PROCESS | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-08-09 | — | — | EP | claimed |
| US-4719054-A | Process for the production of 17α-ethynyl-17β-hydroxy-18-methyl-4,15-estradien-3-one, and novel 3,5-estradien-17-one starting compounds for this process | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-01-12 | — | — | US | claimed |
| US-9012667-B2 | Process for introducing a double bond into position 15, 16 of a steroid | LABORATOIRE THERAMEX (MC) | 2015-04-21 | — | — | US | disclosed |
| EP-2534165-B1 | A PROCESS FOR INTRODUCING A DOUBLE BOND INTO POSITION 15,16 OF A STEROID | THERAMEX (MC) | 2013-07-24 | — | — | EP | disclosed |
| US-20130137885-A1 | PROCESS FOR INTRODUCING A DOUBLE BOND INTO POSITION 15, 16 OF A STEROID | LABORATOIRE THERAMEX (MC) | 2013-05-30 | — | — | US | disclosed |
| EP-2534165-A2 | A PROCESS FOR INTRODUCING A DOUBLE BOND INTO POSITION 15,16 OF A STEROID | Laboratoire Theramex (MC) | 2012-12-19 | — | — | EP | disclosed |
| WO-2011098439-A2 | A PROCESS FOR INTRODUCING A DOUBLE BOND INTO POSITION 15,16 OF A STEROID | LABORATOIRE THERAMEX (MC) | 2011-08-18 | — | — | WO | disclosed |
| EP-2354150-A1 | Process for the preparation of gestodene | LABORATOIRE THERAMEX (MC) | 2011-08-10 | — | — | EP | disclosed |
| EP-0201452-B1 | PROCESS FOR THE PREPARATION OF 17-ALPHA-ETHYNYL-17-BETA-HYDROXY-18-METHYL-ESTRA-4,15-DIEN-3-ONE AND THE STARTING PRODUCTS FOR THIS PROCESS | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-08-09 | — | — | EP | disclosed |
| US-4719054-A | Process for the production of 17α-ethynyl-17β-hydroxy-18-methyl-4,15-estradien-3-one, and novel 3,5-estradien-17-one starting compounds for this process | SCHERING AKTIENGESELLSCHAFT (DE) | 1988-01-12 | — | — | US | disclosed |
| EP-0201452-A2 | Process for the preparation of 17-alpha-ethynyl-17-beta-hydroxy-18-methyl-estra-4,15-dien-3-one and the starting products for this process | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137885-A1 | PROCESS FOR INTRODUCING A DOUBLE BOND INTO POSITION 15, 16 OF A STEROID | CYP17A1, NR5A1, HSD17B7 | SRD5A2 8/4885CYP3A4 86/4885CYP2C9 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.